A single treatment to cure all cancers? Scientists may be one step closer. In a recent study, scientists reported that they successfully tested an antibody treatment that shrank human breast, ovary, colon, bladder, brain, liver and prostate tumors transplanted into mice. The antibody blocks a protein called CD47, which normally sits on the cell surface and issues a don't eat me" signal that prevents the body's immune system from attacking it. About a decade ago, scientists at Stanford University School of Medicine, led by professor of pathology Irving Weissman, discovered that using an antibody to block CD47 cured some cases of leukemia and lymphoma in mice by allowing macrophages to seek and destroy the cancerous cells. In the new study, Weissman's Stanford team showed that the CD47-blocking antibodies may also work against a number of other cancers. The researchers found that CD47 existed on nearly every cell, which suggests that the protein may be common to all cancers. Cancer cells expressed about three times more CD47 than healthy cells. "If the tumor was highly aggressive, the antibody also blocked metastasis. It's becoming very clear that, in order for a cancer to survive in the body, it has to find some way to evade the cells of the innate immune system," said Weissman in a statement. The antibody treatment didn't work in all cases. Some mice injected with breast cancer cells from a human patient showed no changes after treatment. Yet in five mice with breast cancer, the antibody treatment cured them, with no signs of recurrence four months after treatment.
Latest
Latest News
Each news summary is created according to strict standards. Here's how we do it.
Each summary is created using a consistent editorial procedure. The target length is approximately 16 lines of 11-point Arial text in a 650-pixel-wide column. Up to 25% of a summary may be set in bold to emphasize the most important ideas. Summaries are composed of verbatim excerpts presented in the same sequence as they appear in the original news source, with very minor editorial additions. Where material has been omitted between excerpts, the omission is indicated with ellipses (...). Any words added by an editor for clarity or context appear in [brackets]. Our original news editor was Fred Burks. Tod Fletcher edited most summaries from 2007 through 2014, and Mark Bailey has served as news editor since 2014.